Atticus Wealth Management LLC lifted its stake in shares of Zoetis Inc. (NYSE:ZTS – Get Rating) by 22.0% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 677 shares of the company’s stock after acquiring an additional 122 shares during the period. Atticus Wealth Management LLC’s holdings in Zoetis were worth $128,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Norges Bank purchased a new stake in Zoetis in the 4th quarter valued at about $1,067,881,000. Castleview Partners LLC purchased a new stake in Zoetis in the 4th quarter valued at about $6,000,000. BlackRock Inc. raised its holdings in Zoetis by 3.7% in the 4th quarter. BlackRock Inc. now owns 40,315,810 shares of the company’s stock valued at $9,838,266,000 after buying an additional 1,427,812 shares during the period. UBS Asset Management Americas Inc. grew its position in Zoetis by 28.3% in the 3rd quarter. UBS Asset Management Americas Inc. now owns 5,261,396 shares of the company’s stock valued at $1,021,447,000 after acquiring an additional 1,161,674 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC acquired a new position in Zoetis in the 4th quarter valued at about $196,317,000. Institutional investors and hedge funds own 90.73% of the company’s stock.
ZTS stock opened at $174.61 on Monday. The business has a 50 day moving average price of $168.99 and a 200 day moving average price of $191.68. The stock has a market cap of $82.18 billion, a price-to-earnings ratio of 40.05, a PEG ratio of 2.93 and a beta of 0.77. Zoetis Inc. has a fifty-two week low of $154.18 and a fifty-two week high of $249.27. The company has a quick ratio of 1.58, a current ratio of 2.25 and a debt-to-equity ratio of 1.12.
Zoetis (NYSE:ZTS – Get Rating) last posted its earnings results on Thursday, May 5th. The company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.10. The firm had revenue of $2 billion during the quarter, compared to analysts’ expectations of $1.98 billion. Zoetis had a return on equity of 49.62% and a net margin of 26.27%. The firm’s revenue was up 6.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.26 earnings per share. As a group, sell-side analysts anticipate that Zoetis Inc. will post 5.05 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 1st. Shareholders of record on Thursday, July 21st will be paid a $0.325 dividend. This represents a $1.30 dividend on an annualized basis and a yield of 0.74%. The ex-dividend date of this dividend is Wednesday, July 20th. Zoetis’s dividend payout ratio is currently 29.82%.
In related news, Director Willie M. Reed sold 1,855 shares of the company’s stock in a transaction on Friday, June 10th. The stock was sold at an average price of $162.31, for a total transaction of $301,085.05. Following the transaction, the director now owns 6,782 shares of the company’s stock, valued at $1,100,786.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Roxanne Lagano sold 2,167 shares of the company’s stock in a transaction on Tuesday, April 26th. The shares were sold at an average price of $178.96, for a total value of $387,806.32. Following the completion of the sale, the executive vice president now directly owns 23,687 shares in the company, valued at approximately $4,239,025.52. The disclosure for this sale can be found here. 0.12% of the stock is currently owned by insiders.
ZTS has been the subject of several research reports. Citigroup dropped their target price on Zoetis from $232.00 to $208.00 and set a “neutral” rating for the company in a research report on Wednesday, March 9th. StockNews.com downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 26th. Stifel Nicolaus lowered their price objective on Zoetis from $275.00 to $225.00 and set a “buy” rating for the company in a research report on Friday. Finally, The Goldman Sachs Group lowered their price objective on Zoetis from $237.00 to $208.00 and set a “buy” rating for the company in a research report on Thursday, May 19th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $229.75.
Zoetis Profile (Get Rating)
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Further Reading
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Get Rating).
Receive News & Ratings for Zoetis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zoetis and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
